Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostaglandin F2α Receptor (FP) Targeting Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTGFR drug discovery. As a complex GPCR, cell-based assays are essential to preserve native conformation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length Cell Line) | PTGFR Lentivirus Premade Particles For stable cell line construction (Native Conformation). Sequence Verified. Endotoxin <1 EU/µg. |
View PTGFR Products |
| Antigen (Extracellular Domain) | PTGFR N-ECD Partial Recombinant Protein Extracellular domain fragment (Met1-Glu86), HEK293 expressed. High Purity (>95%), Endotoxin <1EU/µg. |
View PTGFR Products |
| Gene Delivery | PTGFR Promise-ORF / Lentivirus Full-length ORF with C-terminal FLAG/HA for stable cell line construction. CMV promoter, Puro selection. Sequence Verified. |
View PTGFR Products |
| Benchmark Ab | Anti-PTGFR (Functional Grade) Recombinant rabbit monoclonal positive control for FACS and Western blot validation. High Purity (>95%). |
View PTGFR Products |
| Validator | PTGFR siRNA Set (3 unique sequences) For specific knockdown verification in calcium flux assays. Chemically synthesized, HPLC purified. |
View PTGFR Products |
| Pathway Partner A | PTGER1 (EP1) Synergistic prostanoid pathway receptor for counter-screening. |
View PTGER1 Products |
| Pathway Partner B | PTGER2 (EP2) Essential for selectivity counter-screening panels; involved in intraocular pressure regulation. |
View PTGER2 Products |
| Pathway Partner C | PTGER4 (EP4) Highly homologous prostanoid receptor; critical for selectivity profiling. |
View PTGER4 Products |
| Pathway Partner D | TBXA2R (TP) Structurally related prostanoid receptor; critical for off-target toxicity profiling. |
View TBXA2R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity & Stability | Lentivirus-mediated stable cell lines preserve native multi-pass membrane folding and glycosylation. Endotoxin controlled (<1EU/µg) to prevent NF-κB activation artifacts. |
| Prostanoid Subfamily Selectivity (EP1-EP4, TP) | Homolog panel available (PTGER1-4, TBXA2R) for rigorous counter-screening; sequence-verified full-length cells or ECD-Fc proteins. |
| Calcium Flux Signal Generation | Compatible with Gα15/16 co-expression systems; cell lines validated for FLIPR/Tetra assays with PGF2α positive control response. |
| Antagonist Internalization Kinetics | Stable cell lines expressing PTGFR-C-terminal tag (FLAG/EGFP) for live-cell imaging and endocytosis quantification. |
| Cross-species Preclinical Evaluation | Human, Cyno, and Mouse PTGFR cell lines available; native glycosylation preserved for translational relevance. |
| Assay Specificity & False Positive Control | Validated PTGFR siRNA set included for knockdown specificity checks; recombinant antibodies available for assay standardization. |
Live PTGFR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Antagonist Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The PTGFR (FP) therapeutic landscape is bifurcated: optimized small-molecule agonists dominate ophthalmology (glaucoma, ocular hypertension) with first-generation prostaglandin analogs (e.g., latanoprost, bimatoprost) remaining the gold standard. However, patient compliance challenges and local side effects (hyperemia) are driving innovation toward sustained-release intraocular implants and next-generation agonists with improved tolerability. Beyond ophthalmology, selective PTGFR antagonists are gaining traction for systemic obstetrics applications (preterm labor, dysmenorrhea), endometriosis, and idiopathic pulmonary fibrosis. The next wave of R&D focuses on biased ligands to separate G-protein and β-arrestin signaling, reducing cardiovascular risks. Assaying these novel modalities requires robust, conformationally accurate cellular models and comprehensive prostanoid family panels for selectivity testing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | AbbVie, Santen, Bausch & Lomb, Novartis, Ube Industries | Glaucoma, Ocular Hypertension | Calcium Flux Assay (Need PTGFR-Lentivirus for stable cell line) |
| Small Molecule Antagonist | ObsEva, Merck KGaA, Ferring, Ogeda SA | Preterm Labor, Endometriosis, Uterine Fibroids, Pulmonary Fibrosis | Selectivity Assay (Need PTGFR/EP/TP homolog panel cells) |
| Sustained Release Implant | Allergan, Glaukos | Refractory Glaucoma | Long-term Potency Evaluation (Need stable assay controls) |
| Biased Ligand | Academic Consortia | Fibrosis, Pain | β-Arrestin vs. G-protein discrimination (Need PTGFR+GRK cell lines) |
| Targeted Osmotic Pump (TOP) | Specialty Ophthalmology | Glaucoma (Agonist) | Receptor internalization kinetics (Need live-cell imaging constructs) |
| Selective Modulator | Early Biotech | Menstrual Disorders | Orthosteric vs. Allosteric site mapping (Need ECD-Fc binding assays) |
| Research Biologic / Tool | Emerging Antibody Programs | Inflammation, Oncology Research | Knockdown/KO validation (Need PTGFR siRNA & ORF) |